Ovid Therapeutics Inc. (OVID)
Ovid Therapeutics Statistics
Share Statistics
Ovid Therapeutics has 71.01M shares outstanding. The number of shares has increased by 0.42% in one year.
| Shares Outstanding | 71.01M |
| Shares Change (YoY) | 0.42% |
| Shares Change (QoQ) | 0.05% |
| Owned by Institutions (%) | 54.66% |
| Shares Floating | 56.76M |
| Failed to Deliver (FTD) Shares | 1.29K |
| FTD / Avg. Volume | 0.33% |
Short Selling Information
The latest short interest is 705.54K, so 0.99% of the outstanding shares have been sold short.
| Short Interest | 705.54K |
| Short % of Shares Out | 0.99% |
| Short % of Float | 1.27% |
| Short Ratio (days to cover) | 1.8 |
Valuation Ratios
The PE ratio is -4.34 and the forward PE ratio is -1.33. Ovid Therapeutics's PEG ratio is -3.17.
| PE Ratio | -4.34 |
| Forward PE | -1.33 |
| PS Ratio | 580.22 |
| Forward PS | 2.1 |
| PB Ratio | 2.59 |
| P/FCF Ratio | -4.95 |
| PEG Ratio | -3.17 |
Enterprise Valuation
Ovid Therapeutics Inc. has an Enterprise Value (EV) of 246.23M.
| EV / Earnings | -4.7 |
| EV / Sales | 628.63 |
| EV / EBITDA | -4.27 |
| EV / EBIT | -4.15 |
| EV / FCF | -5.36 |
Financial Position
The company has a current ratio of 9.55, with a Debt / Equity ratio of 0.18.
| Current Ratio | 9.55 |
| Quick Ratio | 9.55 |
| Debt / Equity | 0.18 |
| Total Debt / Capitalization | 15.42 |
| Cash Flow / Debt | -2.86 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.6% and return on capital (ROIC) is -57.11%.
| Return on Equity (ROE) | -0.6% |
| Return on Assets (ROA) | -0.36% |
| Return on Capital (ROIC) | -57.11% |
| Revenue Per Employee | 15.67K |
| Profits Per Employee | -2.09M |
| Employee Count | 25 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -84.41% in the last 52 weeks. The beta is 0.3, so Ovid Therapeutics's price volatility has been higher than the market average.
| Beta | 0.3 |
| 52-Week Price Change | -84.41% |
| 50-Day Moving Average | 0.77 |
| 200-Day Moving Average | 1.24 |
| Relative Strength Index (RSI) | 30.34 |
| Average Volume (20 Days) | 391.46K |
Income Statement
In the last 12 months, Ovid Therapeutics had revenue of 391.69K and earned -52.34M in profits. Earnings per share was -0.74.
| Revenue | 391.69K |
| Gross Profit | 391.69K |
| Operating Income | -59.28M |
| Net Income | -52.34M |
| EBITDA | -57.69M |
| EBIT | -59.28M |
| Earnings Per Share (EPS) | -0.74 |
Balance Sheet
The company has 27.04M in cash and 16M in debt, giving a net cash position of 11.04M.
| Cash & Cash Equivalents | 27.04M |
| Total Debt | 16M |
| Net Cash | 11.04M |
| Retained Earnings | -277.87M |
| Total Assets | 102.65M |
| Working Capital | 54.2M |
Cash Flow
In the last 12 months, operating cash flow was -45.78M and capital expenditures -137.46K, giving a free cash flow of -45.92M.
| Operating Cash Flow | -45.78M |
| Capital Expenditures | -137.46K |
| Free Cash Flow | -45.92M |
| FCF Per Share | -0.65 |
Margins
Gross margin is 100%, with operating and profit margins of -15.13K% and -13.36K%.
| Gross Margin | 100% |
| Operating Margin | -15.13K% |
| Pretax Margin | -13.36K% |
| Profit Margin | -13.36K% |
| EBITDA Margin | -14.73K% |
| EBIT Margin | -15.13K% |
| FCF Margin | -11.72K% |
Dividends & Yields
OVID does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -139.62% |
| FCF Yield | -121.39% |
Analyst Forecast
The average price target for OVID is $3, which is 466% higher than the current price. The consensus rating is "Buy".
| Price Target | $3 |
| Price Target Difference | 466% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Scores
| Altman Z-Score | -4.61 |
| Piotroski F-Score | 1 |